Palo Alto-based biotech firm, Inceptive, led by former Google AI expert Jakob Uszkoreit, has raised $100 million in funding from Nvidia and Andreessen Horowitz. Inceptive's core innovation involves creating 'biological software' using state-of-the-art AI, envisioning it as a means to encode executable instructions within human cells.

由前Google AI专家Jakob Uszkoreit领导的Inceptive Palo Alto生物技术公司已经从Nvidia和Andreessen Horowitz筹集了1亿美元的资金。Inceptive的核心创新涉及使用最先进的AI创建“生物软件”，将其设想为编码人体细胞内可执行指令的手段。

This transformative approach mirrors a broader trend of biotech startups securing billions in funding to harness AI for drug development, with the sector eyeing a $50 billion market opportunity.Founded just four years ago, Inceptive's valuation surged from $100 million in 2021 to over $300 million in this latest round, attracting investors like Obvious Ventures.

这种变革性的方法反映了生物技术初创公司的更广泛趋势，这些初创公司确保数十亿美元的资金用于药物开发，该行业有望获得500亿美元的市场机会。Inceptive成立仅四年前，其估值从2021年的1亿美元飙升至最新一轮的3亿多美元，吸引了类似明显企业的投资者。

The startup's AI platform designs unique mRNA-based molecules, similar to those used in Pfizer and BioNTech's Covid-19 vaccines. Once validated, Inceptive licenses these molecules to pharmaceutical firms for further development and clinical trials.Collaborating with a major European pharmaceutical company, Inceptive is working on an innovative infectious disease vaccine.

该初创公司的AI平台设计独特的基于mRNA的分子，类似于辉瑞和BioNTech的Covid-19疫苗中使用的分子。一旦验证，Inceptive将这些分子许可给制药公司进行进一步的开发和临床试验。Inceptive与一家主要的欧洲制药公司合作，正在研究一种创新的传染病疫苗。

While mRNA vaccines excelled against Covid-19, replicating their success in other vaccine categories remains a challenge. Inceptive aims to support the growing mRNA drug development landscape, with over 700 programs anticipated by the end of the decade.Numerous biotechs, including Exscientia, Verge Genomics, and Recursion Pharmaceuticals, have introduced AI-driven drugs.

虽然mRNA疫苗优于Covid-19，但在其他疫苗类别中复制其成功仍然是一项挑战。Inceptive旨在支持不断增长的mRNA药物开发领域，预计到十年年底将有超过700个项目。许多生物技术，包括Exscientia，Verge Genomics和Recursion Pharmaceuticals，都引入了AI驱动的药物。

However, the primary hurdle in drug development remains clinical trials..

然而，药物开发的主要障碍仍然是临床试验。。

Uszkoreit's prior work at Google in AI and biology paved the way for his vision. His former colleagues have also founded startups in the race for generative AI talent.Nvidia's venture capital arm, NVentures, is among Inceptive's backers, providing not just funding but access to cutting-edge computing platforms, including advanced chips.Inceptive's impressive growth underscores AI's growing role in pharmaceuticals, promising a revolution in drug discovery.

Uszkoreit之前在谷歌AI和生物学领域的工作为他的愿景铺平了道路。他的前同事还创立了创始AI人才竞赛。Nvidia的风险投资部门NVentures是Inceptive的支持者之一，不仅提供资金，还提供尖端计算平台，包括先进芯片。Inceptive令人印象深刻的增长突显了人工智能在制药领域的日益增长的作用，有望实现药物发现的革命。

For comments and feedback contact: editorial@rttnews.comBusiness News.

有关意见和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision in August 2023

2023年8月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In June 2023

2023年6月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In April 2023

2023年4月面临FDA决定的生物技术股票